Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders

Nutriband marked five years on Nasdaq by highlighting completion of commercial manufacturing scale-up for AVERSA Fentanyl and plans to file an IND, manufacture clinical supplies, and begin human abuse-liability studies. The company said its 2021 uplisting warrants expired on September 30 without extension or repricing, leaving it with no debt and a cleaner capital structure. AVERSA Fentanyl, which has an estimated U.S. peak-sales opportunity of $80 million-$200 million, remains preclinical and subject to FDA approval, financing, and clinical-development risks.

Analysis

NTRB’s near-term setup is primarily a capital-structure and liquidity event, not a fundamental re-rating: expiration of legacy warrants may remove an overhang, but it also eliminates a potential source of exercise proceeds. With clinical work still ahead, the relevant question is whether cash on hand plus operating revenue can fund IND-enabling manufacturing and the human-abuse-liability study; absent disclosed runway, the “no debt” framing should not be confused with no financing risk. Microcap biotech liquidity means any post-warrant relief rally can reverse quickly if an equity raise becomes necessary.

The value inflection is an FDA-cleared IND and credible clarity on the 505(b)(2) pathway over the next 1-3 months, rather than trademark or patent-process updates. A differentiated abuse-deterrence claim could support pricing and partnering leverage versus legacy fentanyl-patch suppliers, but commercial value depends on payer coverage, prescriber adoption, and whether the FDA permits clinically meaningful deterrence labeling. Kindeva is the strategically relevant counterparty: its manufacturing participation de-risks execution relative to a standalone developer, while creating supplier concentration and milestone/cost-sharing economics that could limit NTRB’s eventual gross margin.

Consensus may overvalue headline patent duration and the cited peak-sales range before clinical, labeling, and reimbursement assumptions are validated. The opioid category carries asymmetric regulatory and reputational risk: a safety or CMC delay could materially extend burn, while a favorable FDA interaction alone does not establish approval probability. Retail distribution cited for the consumer-products unit is not a read-through to pharmaceutical commercialization; those channels may modestly offset burn but are unlikely to finance pivotal development at scale.

NDAQ and the named retailers have no investable earnings sensitivity to this development. There is no clean liquid public peer pair; the appropriate benchmark is a small, binary clinical-stage special situation rather than diversified pharma exposure.

Key Decisions for Investors

• Maintain NTRB as watchlist/event-driven only; do not chase a warrant-expiry rally. Initiate a small long only after management discloses cash runway through IND/HAL milestones and FDA accepts the IND, with a 3-6 month catalyst horizon.
• For an approved position, cap sizing at venture-style risk levels (<25 bps of fund NAV) and use a hard thesis stop on an equity financing before IND clearance, an FDA clinical hold, or guidance indicating the HAL study requires materially more capital than available.
• Require validation of three items before underwriting commercial upside: FDA feedback on the 505(b)(2) bridging package, expected abuse-deterrence labeling, and Kindeva cost/milestone obligations. Without these, treat external peak-sales estimates as promotional rather than valuation inputs.
• Avoid sympathy longs in WMT, CVS, TGT, ADS, or NDAQ; their exposure is immaterial. Monitor NTRB’s next 10-Q for cash burn, working-capital conversion in the consumer unit, and any going-concern or subsequent-financing disclosures.